EX-99.2O 3 a2015q18kexhibit992o.htm EXHIBIT 99.2O 2015 Q1 8K Exhibit 992O

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FIRST QUARTER
 
 
 
 
 
 
 
 
 
 
 
2015
 
2014
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 17,374

 
     100.0

 
 $ 18,115
 
     100.0
 
(4.1)
Cost of products sold
      5,282

 
       30.4

 
      5,455
 
       30.1
 
(3.2)
Selling, marketing and administrative expenses
      4,847

 
       27.9

 
      5,183
 
       28.6
 
(6.5)
Research and development expense
      1,899

 
       10.9

 
      1,831
 
       10.1
 
3.7
In-process research and development
—

 
—

 
           18
 
         0.1
 
 
Interest (income) expense, net
         119

 
         0.7

 
         118
 
         0.7
 
 
Other (income) expense, net
       (348)

 
       (2.0)

 
           86
 
         0.5
 
 
Earnings before provision for taxes on income
      5,575

 
       32.1

 
      5,424
 
       29.9
 
2.8
Provision for taxes on income
      1,255

 
         7.2

 
         697
 
         3.8
 
80.1
Net earnings
      4,320

 
       24.9

 
      4,727
 
       26.1
 
(8.6)
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 1.53

 
 
 
 $ 1.64
 
 
 
(6.7)
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,826.0

 
 
 
2,874.7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
22.5

%
 
 
12.9
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 5,630

 
32.4

 
 $ 5,928
 
32.7
 
(5.0)
Net earnings
 $ 4,418

 
25.4

 
 $ 4,693
 
25.9
 
(5.9)
Net earnings per share (Diluted)
 $ 1.56

 
 
 
 $ 1.63
 
 
 
(4.3)
Effective tax rate
21.5

%
 
 
20.8
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, the Ortho-Clinical Diagnostics divestiture, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.











Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
 
FIRST QUARTER
 
 
 
 
 
 
Percent Change
 
 
2015
 
2014
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
 
    U.S.
 
 $ 1,359
 
    1,309
 
     3.8
%
            3.8
 
—

    International
 
      2,031
 
    2,248
 
    (9.7)
 
            3.1
 
      (12.8)

 
 
      3,390
   
    3,557
 
    (4.7)
 
            3.4
 
        (8.1)

 
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
 
    U.S.
 
      4,371
 
    3,740
 
   16.9
 
          16.9
 
—

    International
 
      3,355
 
    3,758
 
  (10.7)
 
            3.7
 
      (14.4)

 
 
      7,726
   
    7,498
 
     3.0
 
          10.2
 
        (7.2)

 
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
 
    U.S.
 
      2,962
   
    3,155
 
    (6.1)
 
          (6.1)
 
—

    International
 
      3,296
 
    3,905
 
  (15.6)
 
          (3.3)
 
      (12.3)

 
 
      6,258
   
    7,060
 
(11.4)
 
          (4.6)
 
        (6.8)

 
 
 
 
 
 
 
 
 
 
 
U.S.
 
      8,692
 
    8,204
 
     5.9
 
            5.9
 
—

International
 
      8,682
 
    9,911
 
  (12.4)
 
            0.8
 
      (13.2)

Worldwide
 
 $ 17,374
 
  18,115
 
    (4.1)
%
            3.1
 
        (7.2)

















Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
 
FIRST QUARTER
 
 
 
 
 
 
Percent Change
 
 
2015
 
2014
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 
 $ 8,692
 
    8,204
 
     5.9
%
            5.9
 
—

 
 
 
 
 
 
 
 
 
 
 
Europe
 
      4,040
 
    4,885
 
  (17.3)
 
            0.3
 
      (17.6)

Western Hemisphere excluding U.S.
 
      1,639
 
    1,695
 
    (3.3)
 
            9.9
 
      (13.2)

Asia-Pacific, Africa
 
      3,003
 
    3,331
 
    (9.8)
 
          (3.0)
 
        (6.8)

International
 
      8,682
 
    9,911
 
  (12.4)
 
            0.8
 
      (13.2)

 
 
  
 
  
 
  
 
  
 
  
Worldwide
 
 $ 17,374
 
  18,115
 
    (4.1)
%
            3.1
 
        (7.2)

















Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Quarter
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
 
2015
 
2014
 
(Decr.)
 
 
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 $ 5,575

 
      5,424

 
             2.8
%
Intangible asset amortization expense
 
 
         312

 
        368

 
 
 
Litigation gain, net
 
 
 
        (402)

 
—

 
 
 
DePuy ASRTM Hip program
 
 
 
         139

 
—

 
 
 
Synthes integration costs
 
 
 
           32

 
        118

 
 
 
Ortho-Clinical Diagnostics divestiture net gain
 
          (26)

 
—

 
 
 
In-process research and development
 
 
—

 
          18

 
 
 
Earnings before provision for taxes on income - as adjusted
 $ 5,630

 
      5,928

 
          (5.0)
 %
 
 
 
 
 
 
 
 
 
 
Net Earnings - as reported
 
 
 
 $ 4,320

 
      4,727

 
          (8.6)
%
Intangible asset amortization expense
 
 
         226

 
        267

 
 
 
Litigation gain, net
 
 
 
        (253)

 
—

 
 
 
DePuy ASRTM Hip program
 
 
 
         122

 
—

 
 
 
Synthes integration costs
 
 
 
           25

 
          84

 
 
 
Ortho-Clinical Diagnostics divestiture net gain
 
          (22)

 
—

 
 
 
In-process research and development
 
 
—

 
          13

 
 
 
Tax benefit associated with Conor Medsystems
 
—

 
       (398)

 
 
 
Net Earnings - as adjusted
 
 
 
 $ 4,418

 
      4,693

 
          (5.9)
 %
 
 
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 
 $ 1.53

 
       1.64

 
          (6.7)
%
Intangible asset amortization expense
 
 
        0.08

 
       0.09

 
 
 
Litigation gain, net
 
 
 
       (0.09)

 
—

 
 
 
DePuy ASRTM Hip program
 
 
 
        0.04

 
—

 
 
 
Synthes integration costs
 
 
 
        0.01

 
       0.03

 
 
 
Ortho-Clinical Diagnostics divestiture net gain
 
       (0.01)

 
—

 
 
 
In-process research and development
 
 
—

 
       0.01

 
 
 
Tax benefit associated with Conor Medsystems
 
—

 
      (0.14)

 
 
 
Diluted Net Earnings per share - as adjusted
 
 $ 1.56

 
       1.63

 
          (4.3)
 %










Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Sales Growth Excluding Acquisitions and Divestitures(A)
 FIRST QUARTER 2015 ACTUAL vs. 2014 ACTUAL
 
 
 
 
 
 
 
 
 
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 
 
Operational % (1)
 
 
 
 
 
 
 
 
 
 WW As Reported:
 
3.4%
 
10.2%
 
(4.6)%
 
3.1%
 U.S.
 
3.8%
 
16.9%
 
(6.1)%
 
5.9%
 International
 
3.1%
 
3.7%
 
(3.3)%
 
0.8%
 
 
 
 
 
 
 
 
 
Women's Health
 
 
 
 
 
 
 
 
K-Y ®
 
0.7
 
 
 
 
 
0.1
 U.S.
 
1.3
 
 
 
 
 
0.2
 International
 
0.4
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
Wound Care / Other
 
 
 
 
 
 
 
 
BENECOL ®
 
0.7
 
 
 
 
 
0.1
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
1.2
 
 
 
 
 
0.3
 
 
 
 
 
 
 
 
 
Diagnostics
 
 
 
 
 
 
 
 
Ortho-Clinical Diagnostics
 
 
 
 
 
5.9
 
2.4
 U.S.
 
 
 
 
 
7.2
 
3.0
 International
 
 
 
 
 
4.8
 
1.9
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
(0.1)
 
 
 
 
 
0.0
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(0.2)
 
 
 
 
 
(0.1)
 
 
 
 
 
 
 
 
 
WW Ops excluding Acquisitions and Divestitures
 
4.7%
 
10.2%
 
1.3%
 
5.7%
 U.S.
 
5.1%
 
16.9%
 
1.1%
 
9.1%
 International
 
4.5%
 
3.7%
 
1.5%
 
3.0%
 
 
 
 
 
 
 
 
 
(1) Operational growth excludes the effect of translational currency
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions and divestitures” is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.







Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2015
 
2014
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
111

 
102

 
8.8
 %
8.8
 %
—
 %
Intl
 
 
400

 
443

 
(9.7
)
(0.9
)
(8.8
)
WW
 
 
511

 
545

 
(6.2
)
1.0

(7.2
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
158

 
160

 
(1.3
)
(1.3
)
—

Intl
 
 
245

 
251

 
(2.4
)
8.8

(11.2
)
WW
 
 
403

 
411

 
(1.9
)
5.0

(6.9
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
405

 
366

 
10.7

10.7

—

Intl
 
 
588

 
645

 
(8.8
)
9.1

(17.9
)
WW
 
 
993

 
1,011

 
(1.8
)
9.6

(11.4
)
 
 
 
 
 
 
 
 
 
 
SKIN CARE
 
 
 
 
 
 
 
 
 
US
 
 
492

 
457

 
7.7

7.7

—

Intl
 
 
411

 
457

 
(10.1
)
1.5

(11.6
)
WW
 
 
903

 
914

 
(1.2
)
4.6

(5.8
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
6

 
24

 
(75.0
)
(75.0
)
—

Intl
 
 
281

 
303

 
(7.3
)
5.5

(12.8
)
WW
 
 
287

 
327

 
(12.2
)
(0.4
)
(11.8
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE/OTHER
 
 
 
 
 
 
 
 
 
US
 
 
187

 
200

 
(6.5
)
(6.5
)
—

Intl
 
 
106

 
149

 
(28.9
)
(19.7
)
(9.2
)
WW
 
 
293

 
349

 
(16.0
)
(12.1
)
(3.9
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
1,359

 
1,309

 
3.8

3.8

—

Intl
 
 
2,031

 
2,248

 
(9.7
)
3.1

(12.8
)
WW
 
$
3,390

 
3,557

 
(4.7
)%
3.4
 %
(8.1
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2015
 
2014
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
1,755

 
1,547

 
13.4
 %
13.4
 %
—
 %
Intl
 
 
708

 
796

 
(11.1
)
3.1

(14.2
)
WW
 
 
2,463

 
2,343

 
5.1

9.9

(4.8
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
1,055

 
997
 
5.8

5.8

—

     US Exports (4)
 
 
181

 
167

 
8.4

8.4

—

     Intl
 
 
364

 
446

 
(18.4
)
(6.2
)
(12.2
)
     WW
 
 
1,600

 
1,610

 
(0.6
)
2.8

(3.4
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
155

 
104

 
49.0

49.0

—

     Intl
 
 
145

 
155

 
(6.5
)
9.7

(16.2
)
     WW
 
 
300

 
259

 
15.8

25.5

(9.7
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
364

 
279

 
30.5

30.5

—

     Intl
 
 
185

 
177

 
4.5

22.5

(18.0
)
     WW
 
 
549

 
456

 
20.4

27.4

(7.0
)
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
14

 
18

 
(22.2
)
(13.7
)
(8.5
)
     WW
 
 
14

 
18

 
(22.2
)
(13.7
)
(8.5
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
412

 
561

 
(26.6
)
(26.6
)
—

Intl
 
 
563

 
639

 
(11.9
)
4.2

(16.1
)
WW
 
 
975

 
1,200

 
(18.8
)
(10.2
)
(8.6
)
     EDURANT
 
 
 
 
 
 
 
 
 
     US
 
 
9

 
5

 
80.0

80.0

—

     Intl
 
 
82

 
76

 
7.9

30.6

(22.7
)
     WW
 
 
91

 
81

 
12.3

33.6

(21.3
)
     OLYSIO / SOVRIAD
 
 
 
 
 
 
 
 
 
     US
 
 
98

 
291

 
(66.3
)
(66.3
)
—

     Intl
 
 
136

 
63

 
*

*

**

     WW
 
 
234

 
354

 
(33.9
)
(26.2
)
(7.7
)
     PREZISTA / PREZCOBIX
 
 
 
 
 
 
 
 
 
     US
 
 
234

 
214

 
9.3

9.3

—

     Intl
 
 
193

 
231

 
(16.5
)
(1.6
)
(14.9
)
     WW
 
 
427

 
445

 
(4.0
)
3.7

(7.7
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
71

 
51

 
39.2

39.2

—

     Intl
 
 
152

 
269

 
(43.5
)
(34.5
)
(9.0
)
     WW
 
 
223

 
320

 
(30.3
)
(22.8
)
(7.5
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2015
 
2014
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (3) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
750

 
601

 
24.8
 %
24.8
 %
—
 %
Intl
 
 
868

 
1,037

 
(16.3
)
(3.2
)
(13.1
)
WW
 
 
1,618

 
1,638

 
(1.2
)
7.1

(8.3
)
     CONCERTA / METHYLPHENIDATE
 
 
 
 
 
 
 
 
 
     US
 
 
126

 
35

 
*

*

—

     Intl
 
 
98

 
115

 
(14.8
)
(3.5
)
(11.3
)
     WW
 
 
224

 
150

 
49.3

58.0

(8.7
)
     INVEGA
 
 
 
 
 
 
 
 
 
     US
 
 
94

 
86

 
9.3

9.3

—

     Intl
 
 
61

 
79

 
(22.8
)
(8.7
)
(14.1
)
     WW
 
 
155

 
165

 
(6.1
)
0.7

(6.8
)
     INVEGA SUSTENNA / XEPLION
 
 
 
 
 
 
 
 
 
     US
 
 
228

 
182

 
25.3

25.3

—

     Intl
 
 
183

 
191

 
(4.2
)
12.5

(16.7
)
     WW
 
 
411

 
373

 
10.2

18.7

(8.5
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
104

 
106

 
(1.9
)
(1.9
)
—

     Intl
 
 
150

 
204

 
(26.5
)
(13.0
)
(13.5
)
     WW
 
 
254

 
310

 
(18.1
)
(9.2
)
(8.9
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
198

 
192

 
3.1

3.1

—

     Intl
 
 
376

 
448

 
(16.1
)
(4.5
)
(11.6
)
     WW
 
 
574

 
640

 
(10.3
)
(2.2
)
(8.1
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
334

 
240

 
39.2

39.2

—

Intl
 
 
774

 
782

 
(1.0
)
15.7

(16.7
)
WW
 
 
1,108

 
1,022

 
8.4

21.2

(12.8
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
66

 
6

 
*

*

—

     Intl
 
 
50

 
4

 
*

*

**

     WW
 
 
116

 
10

 
*

*

**

     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
339

 
408

 
(16.9
)
(4.0
)
(12.9
)
     WW
 
 
339

 
408

 
(16.9
)
(4.0
)
(12.9
)
     ZYTIGA
 
 
 
 
 
 
 
 
 
     US
 
 
253

 
229

 
10.5

10.5

—

     Intl
 
 
303

 
283

 
7.1

26.3

(19.2
)
     WW
 
 
556

 
512

 
8.6

19.2

(10.6
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
15

 
5

 
*

*

—

     Intl
 
 
82

 
87

 
(5.7
)
10.1

(15.8
)
     WW
 
 
97

 
92

 
5.4

20.3

(14.9
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2015
 
2014
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (3) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER(5)
 
 
 
 
 
 
US
 
$
1,120

 
791

 
41.6
 %
41.6
 %
—
 %
Intl
 
 
442

 
504

 
(12.3
)
(0.8
)
(11.5
)
WW
 
 
1,562

 
1,295

 
20.6

25.1

(4.5
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
441

 
319

 
38.2

38.2

—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
441

 
319

 
38.2

38.2

0.0

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
266

 
93

 
*

*

—

     Intl
 
 
12

 
1

 
*

*

**

     WW
 
 
278

 
94

 
*

*

**

     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
163

 
176

 
(7.4
)
(7.4
)
—

     Intl
 
 
106

 
134

 
(20.9
)
(7.5
)
(13.4
)
     WW
 
 
269

 
310

 
(13.2
)
(7.4
)
(5.8
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
250

 
203

 
23.2

23.2

—

     Intl
 
 
324

 
369

 
(12.2
)
(1.7
)
(10.5
)
     WW
 
 
574

 
572

 
0.3

7.1

(6.8
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
4,371

 
3,740

 
16.9

16.9

—

Intl
 
 
3,355

 
3,758

 
(10.7
)
3.7

(14.4
)
WW
 
$
7,726

 
7,498

 
3.0
 %
10.2
 %
(7.2
)%
 
 
 
 
 
 
 
 
 
 
Supplemental Sales Information
 
 
 
 
 
 
 
 
 
 
 
 
2014
 
 
 
Q1
 
Q2
 
Q3
Q4
Full Year
INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
US
 
 
93

 
114

 
169

193

569

Intl
 
 
1

 
3

 
5

8

17

WW
 
 
94

 
117

 
174

201

586

IMBRUVICA
 
 
 
 
 
 
 
 
 
US
 
 
6

 
33

 
42

64

145

Intl
 
 
4

 
9

 
14

28

55

WW
 
 
10

 
42

 
56

92

200

 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2015
 
2014
 
Reported
Operational (1)
Currency

MEDICAL DEVICES (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR CARE
 
 
 
 
 
 
US
 
$
228

 
205

 
11.2
 %
11.2
 %
—
 %
Intl
 
 
301

 
336

 
(10.4
)
3.4

(13.8
)
WW
 
 
529

 
541

 
(2.2
)
6.4

(8.6
)
 
 
 
 
 
 
 
 
 
 
DIABETES CARE
 
 
 
 
 
 
 
 
 
US
 
 
212

 
192

 
10.4

10.4

—

Intl
 
 
272

 
320

 
(15.0
)
0.6

(15.6
)
WW
 
 
484

 
512

 
(5.5
)
4.2

(9.7
)
 
 
 
 
 
 
 
 
 
 
DIAGNOSTICS(6)
 
 
 
 
 
 
 
 
 
US
 
 
—

 
224

 
**

**

—

Intl
 
 
30

 
219

 
(86.3
)
(83.5
)
(2.8
)
WW
 
 
30

 
443

 
(93.2
)
(91.8
)
(1.4
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
1,309

 
1,292

 
1.3

1.3

—

Intl
 
 
1,019

 
1,129

 
(9.7
)
2.9

(12.6
)
WW
 
 
2,328

 
2,421

 
(3.8
)
2.1

(5.9
)
 
 
 
 
 
 
 
 
 
 
SPECIALTY SURGERY / OTHER
 
 
 
 
US
 
 
417

 
417

 
0.0

0.0

—

Intl
 
 
416

 
457

 
(9.0
)
3.5

(12.5
)
WW
 
 
833

 
874

 
(4.7
)
1.8

(6.5
)
 
 
 
 
 
 
 
 
 
 
SURGICAL CARE
 
 
 
 
US
 
 
543

 
539

 
0.7

0.7

—

Intl
 
 
880

 
969

 
(9.2
)
3.0

(12.2
)
WW
 
 
1,423

 
1,508

 
(5.6
)
2.3

(7.9
)
 
 
 
 
 
 
 
 
 
 
VISION CARE
 
 
 
 
 
 
 
 
 
US
 
 
253

 
286

 
(11.5
)
(11.5
)
—

Intl
 
 
378

 
475

 
(20.4
)
(7.5
)
(12.9
)
WW
 
 
631

 
761

 
(17.1
)
(9.0
)
(8.1
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
2,962

 
3,155

 
(6.1
)
(6.1
)
—

Intl
 
 
3,296

 
3,905

 
(15.6
)
(3.3
)
(12.3
)
WW
 
$
6,258

 
7,060

 
(11.4
)%
(4.6
)%
(6.8
)%
 
 
 
 
 
 
 
 
 
 
* Percentage greater than 100%
 
 
 
 
 
 
 
 
 
** Not meaningful
 
 
 
 
 
 
 
 
 
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
 
 
 
 
 
 
 
 
 
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
 
 
 
 
 
 
 
 
 
(5) Previously referred to as Other
 
 
 
 
 
 
 
 
 
(6) Reflects Diagnostics divestiture June 30, 2014